Here’s what you should know:
1. Researchers from both companies will use HiFiBiO’s single-cell screening capabilities to search for and develop antibodies.
2. Takeda is paying HiFiBiO upfront, research and development, milestone and royalty payments for the rights to any developed therapy.
3. HiFiBiO President and CEO Liang Schweizer said, “Takeda is a world leader in oncology, gastroenterology and neuroscience therapeutics. This multi-target partnership further validates our ongoing commitment to these types of open-innovation collaborations to better address unmet medical needs around the world.”
More articles on gastroenterology:
Drs. Jeffrey Nadelson, Jonathan Hlivko & more: 4 GI physicians making headlines
Most read ASC articles: July 19-26
Construction completed on Cypress Creek Medical Pavilion, 16K-square-foot ASC: 3 facts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
